SEARCH

SEARCH BY CITATION

References

  • 1
    Locke GR. The epidemiology of functional gastrointestinal disorders in North America. Gastroenterol Clin North Am 1996; 25: 119.
  • 2
    Sandler RS. Epidemiology of irritable bowel syndrome in the United States. Gastroenterology 1990; 99: 40915.
  • 3
    Talley NJ, Zinsmeister AR, Van Dyke C, et al. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991; 101: 92734.
  • 4
    Drossman DA, Li Z, Andruzzi E, et al. US householder survey of functional gastrointestinal disorders. Dig Dis Sci 1993; 38: 156980.
  • 5
    Farthing MJG. Irritable bowel syndrome. Q J Med 1995; 88: 4514.
  • 6
    Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects. Aliment Pharmacol Ther 2003; 17: 64350.
  • 7
    Thompson WG, Creed FH, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gastroenterol Int 1992; 5: 7591.
  • 8
    Camilleri M, Prather CM. The irritable bowel syndrome: mechanisms and a practical approach to management. Ann Intern Med 1992; 116: 10018.
  • 9
    Zighelboim J, Talley NJ. What are functional bowel disorders? Gastroenterology 1993; 105: 1196201.
  • 10
    Lynn RB, Friedman LS. Irritable bowel syndrome. N Engl J Med 1993; 329: 19405.
  • 11
    Whitehead WE, Winget C, Fedoravicius AS. Learned illness behaviour in patients with irritable bowel syndrome and peptic ulcer. Dig Dis Sci 1982; 295: 5578.
  • 12
    Drossman DA, Creed FH, Olden KW, Svedlund J, Toner BB, Whitehead WE. Psychosocial aspects of the functional gastrointestinal disorders. Gut 1999; 45: II2530.
  • 13
    Drossman DA, Thompson WG. The irritable bowel syndrome: a review and a graduated, multi-component treatment approach. Ann Intern Med 1992; 116(12 Pt 1): 100916.
  • 14
    Crowell MD. The role of serotonin in the pathophysiology of irritable bowel syndrome. Am J Manag Care 2001; 7: S25260.
  • 15
    Farthing MJ. New drugs in the management of the irritable bowel syndrome. Drugs 1998; 56: 1121.
  • 16
    Gershon MD. Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999; 13: 1530.
  • 17
    Talley NJ, Phillips SF, Haddad A, et al. GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci 1990; 35: 47780.
  • 18
    Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999; 13: 114959.
  • 19
    Delvaux M, Louvel D, Mamet JP, Campos-Oriola R, Frexinos J. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998; 12: 84955.
  • 20
    Delvaux M, Frexinos J. Visceral sensitivity and functional bowel disorders: physiopathological role and therapeutic perspectives. Gastroenterol Clin Biol 2001; 25(2 Pt 2): C4253.
  • 21
    Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003; 15: 7986.
  • 22
    Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2004: CD003960.
  • 23
    Patel S, Berrada D, Lembo A. Review of tegaserod in the treatment of irritable bowel syndrome. Expert Opin Pharmacother 2004; 5: 236979.
  • 24
    Müller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT4 receptor agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 165566.
  • 25
    Scott LJ, Perry CM. Tegaserod. Drugs 1999; 58: 4918.
  • 26
    Dumuis A, Sebben M, Bockaert J. BRL 24924: a potent agonist at a non-classical 5-HT receptor positively coupled with adenylate cyclase in colliculi neurons. Eur J Pharmacol 1989; 162: 3814.
  • 27
    Briejer MR, Akkermans LMA, Schuurkes JAJ. Gastrointestinal prokinetic benzamides: The pharmacology underlying stimulation of motility. Pharmacol Rev 1995; 47: 63151.
  • 28
    Camilleri M, McKinzie S, Fox J, et al. A randomized, controlled trial of renzapride on colonic motility in patients with constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2004; 2: 895904.
  • 29
    George A, Meyers NL, Palmer RMJ. Efficacy and safety of renzapride in patients with constipation-predominant IBS: a phase IIb study in the UK primary healthcare setting. Gut 2003; 52: SVI: A91.
  • 30
    Meyers NL, Palmer RMJ, Wray HA, Bloor JR, Wilding IR. Effects of single oral doses of renzapride on gastrointestinal motility in fasted, healthy subjects. Gut 2002; 51: SIII: A137.
  • 31
    Meyers NL, Tack J, Middleton S, et al. Efficacy and safety of renzapride in patients with constipation-predominant irritable bowel syndrome. Gut 2002; 51: SIII, A10.
  • 32
    Peroutka SJ. 5-hydroxytryptamine receptor sub-types: molecular, biochemical and physiological characterisation. TINS 1988; 11: 496500.
  • 33
    Stanniforth DH, Pennick M. Pharmacology of renzapride: a new gastrokinetic benzamide without dopaminergic properties. Eur J Clin Pharmacol 1990; 38: 1614.
  • 34
    Krevsky B, Malmud LS, Maurer AH, Somers MB, Siegel JA, Fisher RS. The effect of oral cisparide on colonic transit. Aliment Pharmacol Ther 1987; 1: 293304.
  • 35
    Ghevens J. Letter – Propulsid Tablets and Suspension (Cisapride). Available from: http://www.fda.gov/medwatch/safety/2000/propul1.htm (last accessed 4 December 2000).
  • 36
    Ferriman A. News. UK licence for cisapride suspended. Br Med J 2000; 321: 259.
  • 37
    Tonini M, De Ponti F, Di Nucci A, Crema F. Review article: cardiac adverse effects of gastrointestinal prokinetics. Aliment Pharmacol Ther 1999; 13: 158891.
  • 38
    Farrington E. Cardiac toxicity with cisapride. Pediatr Nurs 1996; 22: 256.
  • 39
    Manning AP, Thomson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J 1978; 2: 6534.
  • 40
    Thomson WG, Creed F, Drossman DA, et al. Functional bowel disease and functional abdominal pain. Gastroenterol Int 1992; 5: 7591.
  • 41
    Abrahamsson H, Antov S, Bosaeus I. Gastrointestinal and colonic segmental transit time evaluated by a single abdominal X-ray in healthy subjects and constipated patients. Scand J Gastroenterol 1988; 23: 7280.
  • 42
    Mackie AD, Ferrington C, Cowan S, Merrick MV, Baird JD, Palmer KR. The effects of renzapride, a novel prokinetic agent, in diabetic gastroparesis. Aliment Pharmacol Ther 1991; 2: 13542.
  • 43
    Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52: 6716.
  • 44
    Berardi RR. Safety and tolerability of tegaserod in irritable bowel syndrome management. J Am Pharm Assoc (Wash DC). 2004; 44: 4151.